BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Week In Review | Aug 17, 2017
Clinical News

Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) reported data from 24 heavily treated patients with advanced solid tumors in the dose-escalation part 1 of a Phase I trial showing that 8-288 mg/m 2 /day doses of CYC065 given...
BC Week In Review | Jul 21, 2017
Financial News

Cyclacel raises $13.2M in follow-on

Cancer company Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) raised $13.2 million through the sale of 2.2 million class A units at $2 and 8,872 class B units at $1,000 in a follow-on underwritten by Ladenburg Thalmann on...
BC Week In Review | Apr 27, 2017
Clinical News

CYC140: Preclinical data

In mouse xenograft models of esophageal cancer and acute leukemia, CYC140 significantly reduced mean tumor volume vs. vehicle-treated controls. Data were presented at the American Association for Cancer Research meeting in Washington, D.C. CYC140 is...
BC Week In Review | Apr 13, 2017
Clinical News

CYC065: Preclinical data

In vitro , CYC065 inhibited growth, triggered apoptosis and induced anaphase catastrophe in murine and human lung cancer cells with known high metastatic potential. CYC065 also inhibited migration and invasion of lung cancer cells. Data were...
BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BC Week In Review | Feb 24, 2017
Clinical News

Sapacitabine: Additional Ph III SEAMLESS data

The open-label, international Phase III SEAMLESS trial in 491 newly diagnosed AML patients ages ≥70 years who were not candidates for, or who refused, intensive induction chemotherapy showed that alternating cycles of sapacitabine and Dacogen...
BC Extra | Feb 23, 2017
Clinical News

Cyclacel's sapacitabine fails in Phase III AML trial

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) lost $1.36 (25%) to $4.05 on Thursday after its sapacitabine ( CYC682 ) missed the primary endpoint in the pivotal Phase III SEAMLESS trial to treat newly diagnosed acute myelogenous leukemia in elderly...
BC Innovations | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)

Infectious disease INDICATION: Viral infection Cell culture studies suggest the pan-caspase inhibitor emricasan, the generic antihelminthic niclosamide or CDK inhibitors could help treat Zika. In a Zika virus-infected human glioblastoma cell line, screening of 6,000...
BC Innovations | Aug 18, 2016
Translation in Brief

The CDK5 checkpoint

Despite the clinical success of checkpoint inhibitors, immuno-oncologists still have an incomplete understanding of how the receptors and their ligands prevent antitumor immunity. In a new study, Case Western Reserve University researchers found mechanistic data...
Items per page:
1 - 10 of 282
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BC Week In Review | Aug 17, 2017
Clinical News

Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) reported data from 24 heavily treated patients with advanced solid tumors in the dose-escalation part 1 of a Phase I trial showing that 8-288 mg/m 2 /day doses of CYC065 given...
BC Week In Review | Jul 21, 2017
Financial News

Cyclacel raises $13.2M in follow-on

Cancer company Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) raised $13.2 million through the sale of 2.2 million class A units at $2 and 8,872 class B units at $1,000 in a follow-on underwritten by Ladenburg Thalmann on...
BC Week In Review | Apr 27, 2017
Clinical News

CYC140: Preclinical data

In mouse xenograft models of esophageal cancer and acute leukemia, CYC140 significantly reduced mean tumor volume vs. vehicle-treated controls. Data were presented at the American Association for Cancer Research meeting in Washington, D.C. CYC140 is...
BC Week In Review | Apr 13, 2017
Clinical News

CYC065: Preclinical data

In vitro , CYC065 inhibited growth, triggered apoptosis and induced anaphase catastrophe in murine and human lung cancer cells with known high metastatic potential. CYC065 also inhibited migration and invasion of lung cancer cells. Data were...
BioCentury | Apr 7, 2017
Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...
BC Week In Review | Feb 24, 2017
Clinical News

Sapacitabine: Additional Ph III SEAMLESS data

The open-label, international Phase III SEAMLESS trial in 491 newly diagnosed AML patients ages ≥70 years who were not candidates for, or who refused, intensive induction chemotherapy showed that alternating cycles of sapacitabine and Dacogen...
BC Extra | Feb 23, 2017
Clinical News

Cyclacel's sapacitabine fails in Phase III AML trial

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) lost $1.36 (25%) to $4.05 on Thursday after its sapacitabine ( CYC682 ) missed the primary endpoint in the pivotal Phase III SEAMLESS trial to treat newly diagnosed acute myelogenous leukemia in elderly...
BC Innovations | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)

Infectious disease INDICATION: Viral infection Cell culture studies suggest the pan-caspase inhibitor emricasan, the generic antihelminthic niclosamide or CDK inhibitors could help treat Zika. In a Zika virus-infected human glioblastoma cell line, screening of 6,000...
BC Innovations | Aug 18, 2016
Translation in Brief

The CDK5 checkpoint

Despite the clinical success of checkpoint inhibitors, immuno-oncologists still have an incomplete understanding of how the receptors and their ligands prevent antitumor immunity. In a new study, Case Western Reserve University researchers found mechanistic data...
Items per page:
1 - 10 of 282